Robert L. Schlossman

Viral antigen‐specific CD8+ T‐cell responses are impaired in multiple myeloma

N. Munshi, P. Richardson, K. Anderson, 2003, British journal of haematology.

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

P. Richardson, D. Kufe, D. Chauhan, 2004, British journal of haematology.

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

J. Laubach, P. Richardson, C. Mitsiades, 2012, European journal of haematology.

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

K. Anderson, N. Munshi, J. Laubach, 2014, British journal of haematology.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

D. Esseltine, P. Wen, K. Anderson, 2005 .